Antihypercholesterolemic compounds

ABSTRACT

Novel 3-hydroxy-3-methylglutaryl-Coenzyme A(HMG-CoA) reductase inhibitors, which are useful as antihypercholesterolemic agents and are represented by the following general structural formulae (I) and (II)    &lt;IMAGE&gt;  (I)   &lt;IMAGE&gt; (II)  and pharmaceutically acceptable salts of the compound (II) in which Z is hydrogen are disclosed.

This is a division of application Ser. No. 177,806 filed Apr. 11, 1988now U.S. Pat. No. 4,847,306 issued July 11, 1989.

BACKGROUND OF THE INVENTION

Hypercholesterolemia is known to be one of the prime risk factors forischemic cardiovascular disease such as arteriosclerosis. To date, thereis still no effective antihypercholesterolemic agent commerciallyavailable that has found wide patient acceptance. The bile acidsequestrants seem to be moderately effective but they must be consumedin large quantities, i.e. several grams at a time and they are not verypalatable.

There are agents known, however, that are very activeantihypercholesterolemic agents that function by limiting cholesterolbiosynthesis by inhibiting the enzyme, HMG-CoA reductase. These agentsinclude the natural fermentation products compactin and mevinolin and avariety of semi-synthetic and totally synthetic analogs thereof. Thenaturally occurring compounds and their semi-synthetic analogs have thefollowing general structural formulae: ##STR2## wherein: Z is hydrogen,C₁₋₅ alkyl or C₁₋₅ alkyl substituted with a member of the groupconsisting of phenyl, dimethylamino, or acetylamino;

R is ##STR3## wherein Q is ##STR4## R₂ is H or OH: R₁ is hydrogen ormethyl; and a, b, c, and d represent optional double bonds, especiallywhere b and d represent double bonds or a, b, c, and d are all singlebonds.

U.S. Pat. No. 4,517,373 discloses semi-synthetic compounds representedby the above general formula wherein R is ##STR5##

U.S. Pat. No. 4,346,227 and U.S. Pat. No. 4,448,979 also disclosesemi-synthetic compounds represented by the above general formulawherein R is ##STR6##

Japanese unexamined patent application J59-122,483-A discloses asemi-synthetic compound represented by the above general formula whereinR is ##STR7## in which R₃ is hydrogen or methyl;

R₄ is hydrogen, halogen or haloalkyl;

R₅ is hydrogen, halogen or loweralkyl

and R₆ is halogen, N₃, hydroxy, thio, amino, loweralkoxy, loweralkylthioand aralkylthio.

U.S. Pat. No. 4,444,784 discloses 8'-acyloxy derivatives of compactin,mevinolin and the dihydro and tetrahydro analogs thereof. Genericallydisclosed are the compounds represented by the above general formulawherein R is ##STR8## in which R₇ is hydrogen or methyl and R₈ is C₃₋₁₀cycloalkyl.

SUMMARY OF THE INVENTION

This invention relates to novel compounds which are HMG-CoA reductaseinhibitors and are useful as antihypercholesterolemic agents.Specifically, the compounds of this invention are semi-synthetic analogsof compactin, mevinolin, hydroxylated compactin and hydroxylatedmevinolin and the dihydro and tetrahydro analogs thereof which possess aspecifically substituted cycloalkyl 8'-ester acyl moiety. Additionally,pharmaceutical compositions of these novel compounds, as the soletherapeutically active ingredient, and in combination with bile acidsequestrants are disclosed.

DETAILED DESCRIPTION OF THE INVENTION

The specific HMG-CoA reductase inhibitors of this invention are thecompounds represented by the following general structural formulae (I)and (II): ##STR9## wherein: q is 0 to 5;

n is 2 to 7;

R¹ is C₁₋₆ alkyl, C₁₋₆ alkyl substituted with a group selected fromhalogen, hydroxy, C₁₋₃ alkylthio, C₁₋₃ alkylsulfinyl and C₁₋₃alkylsulfonyl, C₁₋₆ alkylthio, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyl,C₃₋₇ cycloalkylthio, C₃₋₇ cycloalkylsulfinyl, C₃₋₇ cycloalkylsulfonyl,C₃₋₇ cycloalkyl, phenyl, or phenyl substituted with X and Y;

R² is hydrogen or hydroxy;

R³ and R⁴ independently are hydrogen, C₁₋₃ alkyl, C₃₋₇ Cycloalkyl,phenyl or phenyl substituted with X and Y and when q is 2 to 5, each ofthe R³ s and R⁴ s are independently hydrogen, C₁₋₃ alkyl, C3-7cycloalkyl or only one of the R³ s and R⁴ s is phenyl or substitutedphenyl;

A is ##STR10## in which R⁵ is hydrogen or hydroxy; B is CHR⁶ in which R⁶is hydrogen or hydroxy;

a, b, c and d represent single bonds, one of a, b, c or d represents adouble bond or both a and c or both b and d represent double bonds,provided that when a is a double bond, A is ##STR11## and when d is adouble bond, B is ##STR12## X and Y independently are hydrogen, halogen,trifluoromethyl, C₁₋₃ alkyl, nitro, cyano or a group selected from;

a) R⁷ O(CH₂)_(m) in which m is 0 to 3 and R⁷ is hydrogen, C₁₋₃ alkyl orhydroxy-C₁₋₃ alkyl;

b) ##STR13## in which R⁸ is hydrogen, C₁₋₃ alkyl, hydroxy-C₂₋₃ alkyl,phenyl, naphthyl, amino-C₁₋₃ alkyl, C₁₋₃ alkylamino-C₁₋₃ alkyl, di(C₁₋₃alkyl)amino-C₁₋₃ alkyl, hydroxy-C₂₋₃ alkylamino-C₁₋₃ alkyl ordi(hydroxy-C₂₋₃ alkyl)amino-C₁₋₃ alkyl;

c) ##STR14## in which R⁹ is hydrogen, C₁₋₃ alkyl, hydroxy-C₁₋₃ alkyl,C₁₋₃ alkoxy-C₁₋₃ alkyl, phenyl or naphthyl;

d) R¹⁰ R¹¹ N(CH₂)_(m), ##STR15## or ##STR16## in which R¹⁰ and R¹¹independent are hydrogen, C₁₋₃ alkyl, hydroxy-C₂₋₃ alkyl or togetherwith the nitrogen atom to which they are attached form a heterocyclegroup selected from piperidinyl, pyrrolidinyl, piperazinyl, morpholinylor thiomorpholinyl;

e) R¹² S(O)_(p) (CH₂)_(m) in which p is 0 to 2 and R¹² is hydrogen, C₁₋₃alkyl, amino, C₁₋₃ alkylamino or di alkyl)amino;

Z is hydrogen, C₁₋₅ alkyl or C₁₋₅ alkyl substituted with a groupselected from phenyl, dimethylamino or acetylamino; and

pharmaceutically acceptable salts of the compounds of the formula (II)in which Z is hydrogen.

One embodiment of this invention is the class of compounds of theformula (I) and (II) wherein q is 0, R², R⁵ and R⁶ are hydrogen and a,b, c and d represent single bonds or both b and d represent doublebonds. Particular compounds of this embodiment are those of the formulae(I) and (II) wherein n is 2 to 5 and R¹ is C₁₋₆ alkyl, hydroxy-C₁₋₆alkyl, C₁₋₆ alkylthio, phenyl or hydroxyphenyl.

Illustrative of this embodiment when n is 2 is the following compound:

6(R)-[2-[8(S)-(1-Methylcyclopropanecarbonyloxy)-2(S),6(R)-dimethyl1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one.

Illustrative of this embodiment when n is 3 are the following compounds:

(1)6(R)-[2-[8(S)-(1-Methylcyclobutanecarbonyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one;

(2)6(R)-[2-[8(S)-(1-Methylthiocyclobutanecarbonyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one;

(3)6(R)-[2-[8(S)-[1-(3-Hydroxypropyl)cyclobutanecarbonyloxy]-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one;

(4)6(R)-[2-[8(S)-[1-[(4-Hydroxyphenyl)methyl]cyclobutanecarbonyloxy]-2(S),6(R)dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one;

(5)6(R)-[2-[8(S)-[1-(1-Hydroxymethyl)cyclobutanecarbonyloxy]-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one;and

(6)6(R)-[2-[8(S)-[(1-Phenylmethyl)cyclobutanecarbonyloxy)]-2(S),6(R)-dimethyl-1,2,6,7,7,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one.

Illustrative of this embodiment when n is 4 are the following compounds:

(1)6(R)-[2-[8(S)-(1-Methylcyclopentanecarbonyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one;and

(2)6(R)-[2-[8(S)-(1-Methylthiocyclopentanecarbonyl)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one.

Illustrative of this embodiment when n is 5 is the following compound:

6(R)-[2-[8(S)-(1-Methylcyclohexanecarbonyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one.

Another embodiment of this invention is the class of compounds of theformula (II) wherein Z is hydrogen or C₁₋₅ alkyl and pharmaceuticallyacceptable salts of the compounds of the formula (II) wherein Z ishydrogen.

The pharmaceutically acceptable salts of this invention include thoseformed from cations such as sodium, potassium, aluminum, calcium,lithium, magnesium, zinc, and from bases such as ammonia,ethylenediamine, N-methylglucamine, lysine, arginine, ornithine,choline, N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine,procaine, N-benzylphenethylamine, diethylamine, piperazine,tris(hydroxymethyl)aminomethane, and tetramethylammonium hydroxide.

The compounds of formula (I) are conveniently prepared from compactin,mevinolin, or the appropriate dihydro or tetrahydro analog thereof viathe following general synthetic pathways: ##STR17##

The starting materials compactin, mevinolin, and their dihydro andtetrahydro analogs are readily available or may be prepared according tofermentation procedures disclosed in U.S. Pat. No. 3,983,140, U.S. Pat.No. 4,049,495, U.S. Pat. No. 4,231,938, U.S. Pat. No. 4,294,846, U.S.Pat. No. 4,343,814 and the hydrogenation procedures disclosed in U.S.Pat. No. 4,351,844.

According to Pathway A, the appropriate starting material of formula (1)is hydrolyzed under the conditions disclosed in U.S. Pat. No. 4,444,784to afford the compounds of formula (2). The 4-hydroxy function in thelactone moiety of the compounds of formula (2) is protected with asuitable protecting agent, exemplified here as a dimethyl-t-butylsilylgroup, according to the procedure disclosed in U.S. Pat. No. 4,444,784to give the compounds of the formula (3).

Acylation of the 8'-hydroxy group of the compounds of the formula (3) isaccomplished under suitable conditions using the reagents of formula (4)wherein q, n, R¹, R³ and R⁴ are described above and W is hydroxy orhalogen, especially chloro or bromo. The protecting groups of theresultant compounds of the formula (5) are removed utilizing suitableconditions to afford the compounds of the formula (I).

According to Pathway B, the 2-carbonyl function in the lactone moiety ofthe compounds of formula (6) is reduced to the lactol function understandard conditions to yield the compounds of the formula (7). The2-hydroxy function in the lactol moiety of the compounds of the formula(7) is then protected with a suitable protecting group, exemplified hereas the tetrahydropyran group (THP). The compounds of the formula (8) areconverted to the compounds of the formula (9). The compounds of theformula (9) so produced are reacted with an acylating agent of theformula ##STR18## wherein n and W are defined above to afford thecompounds of the formula (10). The enolates of the compounds of theformula (10) are then reacted with the appropriately alkylating agent,##STR19## wherein q, R¹, R³ and R⁴ are described above, to give thecompounds of formula (11). The THP protecting group is removed underacidic conditions and the resulting hydroxy function is oxidized to formthe 2-carbonyl function of the lactone moiety of the compounds of theformula (5). The remaining protecting groups on the compounds of theformula (5) are removed under standard conditions to yield the compoundsof the formula (I).

For the compounds of this invention wherein the polyhydronaphthyl moietyis substituted with a hydroxy group, the compounds of the formula (4)are subject to a microbiological hydroxylation after the removal of theprotecting groups utilizing the general procedures disclosed in U.S.Pat. No. 4,346,227, U.S. Pat. No. 4,448,979, U.S. Pat. No. 4,517,373 andJapanese Pat. No. Application J-60-130,548.

The compounds of the formula (II) wherein Z is hydrogen or apharmaceutically acceptable salt thereof are readily prepared by themild basic hydrolysis of the lactone moiety of the compounds of formula(I), careful acidification and formation of the appropriate saltutilizing standard procedures.

The compounds of the formula (II) wherein Z is C₁₋₅ alkyl or asubstituted C₁₋₅ alkyl may be conveniently prepared by the proceduresdescribed in U.S. Pat. No. 4,342,767.

The compounds of this invention are useful as antihypercholesterolemicagents for the treatment of arteriosclerosis, hyperlipidemia, familialhypercholesterolemia and the like diseases in humans. They may beadministered orally or parenterally in the form of a capsule, a tablet,an injectable preparation or the like. It is usually desirable to usethe oral route. Doses may be varied, depending on the age, severity,body weight and other conditions of human patients but daily dosage foradults is within a range of from about 2 mg to 2000 mg (preferably 2 to100 mg) which may be given in two to four divided doses. Higher dosesmay be favorably employed as required.

The compounds of this invention may also be coadministered withpharmaceutically acceptable nontoxic cationic polymers capable ofbinding bile acids in a non-reabsorbable form in the gastrointestinaltract. Examples of such polymers include cholestyramine, colestipol andpoly[methyl-(3-trimethylaminopropyl)imino-trimethylene dihalide]. Therelative amounts of the compounds of this invention and these polymersis between 1:100 and 1:15,000.

The intrinsic HMG-CoA reductase inhibition activity of the claimedcompounds is measured in the in vitro protocol published in J. Med.Chem., 28, P. 347-358 (1985) and described below:

Isolation of HMG-CoA Reductase

Male Holtzman Sprague-Dawley rate (225-250g) were kept on reversedlighting and fed Purina rat chow containing 3% cholestyramine for 7 dayspreceding their sacrifice by CO₂ asphyxiation. Livers were removed 6hours into the dark cycle and used immediately to prepare microsomes.HMG-CoA reductase was solubilized from the freshly prepared microsome bythe method of Heller and Shrewsbury [J. Biol. Chem., 1976, 251,3815],and purified through the second ammonium sulfate precipitation step asdescribed by Kleinsek et al. [Proc. Natl. Acad. Sci. USA, 1977, 74,1431]. The enzyme preparation was tested for HMG-CoA reductase potencyand diluted with 100 mM phosphate buffer (pH 7.2) so that 100 μL of theenzyme solution, when added to the assay control, gave a value of50,000-60,000 dpm. The enzyme preparation was stored at -80° C.

HMG-CoA Reductase Inhibition Assay

The assay is essentially the procedure of Shefer et al., [J. Lipid Res.,1972, 13, 402]. The complete assay medium contained the following in atotal volume of 0.8 mL: phosphate buffer, pH 7.2, 100 mM; MgCl₂, 3 mM;NADP, 3 mM; glucose 6-phosphate, 10 mM; glucose-6-phosphatedehydrogenase, 3 enzyme units; reduced glutathione, 50 mM; HMG-CoA(glutaryl-3- ^(14C), New England Nuclear), 0.2 mM (0.1 μCi); andpartially purified enzyme stock solution, 100 μL.

Test compounds or compactin (after first being converted to the sodiumsalt of their dihydroxy acid form in situ by addition of 1 N NaOH (1equiv)) were added to the assay system in 10-μL volumes atmulticoncentration levels. After a 40-minute incubation at 37° C. withshaking and exposure to air, the reaction was stopped by the addition of0.4 mL of 8 N HCl. After an additional 30-minute incubation period at37° C. to ensure the complete lactonization of mevalonic acid tomevalonolactone, 0.2 mL of the mixture was added to an 0.5×5.0 cm columncontaining 100-200-mesh Bio-Rex 5, chloride form (Bio-Rad), wetted withdistilled water, as described by Alberts et al. [J. Proc. Natl. Acad.Sci. U.S.A., 1980, 77, 3957]. The unreacted [¹⁴ C]HMG-CoA was absorbedon the resin and the [¹⁴ C]mevalonol-acetone was eluted with distilledwater (2×1 mL) directly into 7-mL scintillation vials. Five millilitersof Aquasol- 2 (New England Nuclear) was added to each vial, andradioactivity was measured in a Packard Tri Carb Prias scintillationcounter. IC₅₀ values were determined by plotting percentage inhibitionagainst test compound concentration and fitting a straight line to theresulting data by using the least-squares method. For estimation ofrelative inhibitory potencies, compactin was assigned a value of 100 andthe IC₅₀ value of the test compound was compared with that of compactindetermined simultaneously.

Representative of the intrinsic HMG-CoA reductase inhibitory activitiesof the claimed compounds tabulated for a number of the claimed compoundsare the relative potencies for said compound.

                  TABLE 1                                                         ______________________________________                                         ##STR20##                                                                    T                     Relative Potency.sup.1                                  ______________________________________                                         ##STR21##            76                                                       ##STR22##            171                                                      ##STR23##            240                                                      ##STR24##            100                                                      ##STR25##            200                                                      ##STR26##            88                                                       ##STR27##            156                                                      ##STR28##            188                                                      ##STR29##            167                                                      ##STR30##            217                                                     ______________________________________                                    

Included within the scope of this invention is the method of treatingarteriosclerosis, familial hypercholesterolemia or hyperlipidemia whichcomprises administering to a subject in need of such treatment anontoxic therapeutically effective amount of the compounds of formulae(I) or (II) or pharmaceutical compositions thereof.

The following examples illustrate the preparation of the compounds ofthe formulae (I) and (II) and their incorporation into pharmaceuticalcompositions and as such are not to be considered as limiting theinvention set forth in the claims appended hereto.

EXAMPLE 1 Preparation of6(R)-[2-[8(S)-(1-Methylcyclopropanecarbonyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one](a)6(R)-[2-[8(S)-(1-Methylcyclopropanecarbonyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)hexahydronaphthyl-1(S)]ethyl]-4(R)-(dimethyl-tert-butylsilyloxy)3,4,5,6-tetrahydro-2H-pyran-2-one(1a)

To a stirred solution of6(R)-[2-[8(S)hydroxy-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl-4(R)-(dimethyl-tert-butylsilyloxy)-3,4,5,6-tetrahydro-2H-pyran-2-one(1.0 g, 2.3 mmol) and 4-dimethylaminopyridine (0.17 g, 1.38 mmol) inpyridine (15 ml) was added under nitrogen 1-methylcyclopropanecarbonylchloride (0.82 g, 6.9 mmol). The resulting mixture was stirred at roomtemperature for 1 hour, then heated at 60° C. for 8 hours. More4-dimethylaminopyridine (30 mg) and 1-methylcyclopropanecarbonylchloride (0.27 g) were added and the resulting mixture was heated at 60°C. for 8 hours. The reaction mixture was poured into cold water andextracted with ether. The ethereal extract was washed successively with1N HCl, 5% NaHCO₃ and brine. It was dried over MgSO₄, filtered andevaporated to leave an oily residue which was purified by flashchromatography on a silica gel column. Elution of the column with CH₂Cl₂ :acetone=200:1 (v:v) gave the desired product as a pale yellow oil:NMR (CDCl₃)δ 0.09 (6H, s), 0.89 (9H, s), 1.07 (3H, d, J=7 Hz), 1.25 (3H,s), 2.57 (2H, d, J=4 Hz), 4.30 (1H, m), 4.60 (1H, m), 5.27 (1H, m), 5.50(1H, m), 5.74 (1H, dd, J=10 Hz, 5 Hz), 5.98 (1H, d, J=10 Hz).

(b)6(R)-[2-[8(S)-(1-Methylcyclopropanecarbonyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy3,4,5,6-tetrahydro-2H-pyran-2-one

A solution of tetra-n-butylammonium fluoride solution (1M in THF, 12 ml,12 mmo)) was added to a stirred solution of the Compound 1(a) (0.7 g,1.35 mmol) and acetic acid (1.45 ml, 25 mmol) in THF (75 ml). Theresulting mixture was stirred under nitrogen for 20 hours. The reactionmixture was poured into cold water and extracted with ether. Thisextract was washed with 5% NaHCO₃ and brine, dried, filtered andconcentrated to give a residue. This residue was purified by flashchromatography. Elution of the column with CH₂ Cl₂ :acetone 10:1 (v:v)afforded the desired products which crystallizes after the triturationwith hexane:2-propanol=9:1 (v:v). The solid product was collected byfiltration and recrystallized from ether/ethyl acetate/hexane: m.p.181-2° C.; NMR (CDCl₃)δ 0.65 (2H, m), 0.90 (3H, d, J=7 Hz), 1.17 (3H, d,J=7 Hz), 1.26 (3H, s), 2.63 (1H, m of d, J=18 Hz), 2.75 (1H, d of d,J=18 Hz, 5 Hz), 4.39 (1H, m), 4.64 (1H, m), 5.28 (1H, m), 5.52 (1H, m),5.77 (1H, d of d, J=10, 5 Hz), 5.98 (1H, d, J=10 Hz).

Anal. Calcd. for C₂₄ H₃₄ O₅ : C, 71.61; H, 8.51.

Found: C, 71.69; H, 8.52.

EXAMPLE 2 Preparation of6(R)-[2-[8(S)-(1-Methylcyclohexanecarbonyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one(a)6(R)-[2-[8(S)-(1-Methylcyclohexanecarbonyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-(tert-butyldimethylsilyloxy)-3,4,5,6-tetrahydro-2H-pyran-2-one(2a)

A solution of 2,6-dichloro-4-methoxy-1,3,5-triazine (0.41 g, 2.3 mmol)in methylene chloride (10 ml) was added dropwise to a stirred solutionof 1-methylcyclohexanecarboxylic acid (0.33 g, 2.3 mmol) andN-methylmorpholine (0.260 ml, 2.6 mmol) in methylene chloride (12 ml).The resulting mixture was stirred at -5° C. for 2 hours before asolution of6(R)-[2-[8(S)-hydroxy-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-(tert-butyldimethylsilyloxy)-3,4,5,6-tetrahydro-2H-pyran-2-one(0.50 g, 1.1 mmol) in methylene chloride (10 ml) was added. Theresulting mixture was heated at reflux for 20 hours, cooled, dilutedwith ether (100 ml), then washed successively with water, 1N HCl, brine,5% NaHCO₃ and brine. It is dried over magnesium sulfate, filtered andevaporated to yield a residue which was applied to a silica gel column.The column was eluted with CH₂ Cl₂ :acetone=200:1 (v:v). Fractionscontaining the pure Product were combined and evaporated to afford thetitle compound as a pale yellow oil: NMR (CDCl₃) δ=0.09 (6H, s), 0.91(9H, s), 1.21 (3H, d, J=7 Hz), 1.27 (3H, s), 2.60 (2H, d, J=4 Hz), 4.30(1H, m), 4 61 (1H, m), 5.3-5.6 (2H, m), 5.75 (1H, d of d, J=10, 5 Hz),6.01 (1H, d, J=10 Hz).

(b)6(R)-[2-[8(S)-(1-Methylcyclohexanecarbonyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one

Utilizing the general procedure of Example 1(b), the compound (2a) wasconverted into the desired product as a viscous oil; NMR (CDCl₃) δ=0.90(3H, d, J=7 Hz), 1.11 (3H, d, J=7 Hz), 1.17 (3H, s), 4.40 (1H, m), 4.65(1H, m), 5.45 (1H, m), 5.52 (1H, m), 5.80 (1H, d of d, J=10 Hz, 5 Hz),6.02 (1H, d, J=10 Hz).

EXAMPLE 3 Preparation of6(R)-[2-[8(S)-(1-Methylcyclobutanecarbonyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one(a)6(R)-[2-(8(S)-Cyclobutanecarbonyloxy-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S))ethyl]-4(R)-(tert-butyldimethylsilyloxy)-2-(2-tetrahydropyranyloxy)-3,4,5,6-tetrahydro-2H-pyran(3a)

Cyclobutanecarbonyl chloride (1.37 g, 11.6 mmol) was added undernitrogen to a stirred solution of6(R)-[2-(8(S)-hydroxy-2(S),6(R)-dimethyl1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S))ethyl]-4(R)(tert-butyldimethylsilyloxy)-2-(2-tetrahydropyranyloxy)-3,4,5,6-tetrahydro-2H-pyran(2 g, 3.84 mmol) and 4-dimethylaminopyridine (0.28 g, 2.28 mmol) inpyridine (28 ml) with the cooling of a cold water bath. The resultingmixture was stirred at room temperature for 12 hours. The reactionmixture was then poured into water and extracted with ether. The extractwas successively washed with diluted HCl (to remove pyridine) andaqueous NaHCO₃ After the drying and filtration, the filtrate wasconcentrated to give a residue which was subsequently purified by flashcolumn chromatography. Elution of the column with CH₂ Cl₂ :acetone=200:1(v:v) afforded the desired product as a pale yellow oil NMR (CDCl₃)δ=0.06 (6H, s), 0.92 (9H, s), 1.07 (3H, d, J=7 Hz), 3.06 (1H, q, J=8Hz), 4.26 (1H, m), 4.8-5.2 (2H, m), 5.33 (1H, m), 5.50 (1H, m), 5.75(1H, d of d, J=10, 5 Hz), 6.00 (1H, d, J=10 Hz).

(b)6(R)-[2-[8(S)-(1-Methylcyclobutanecarbonyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-(tert-butyldimethylsilyloxy)-2-(2-tetrahydropyranyloxy)-3,4,5,6-tetrahydro-2H-pyran(3b)

To a stirred solution of diisopropylamine (112 μl,0.8 mmol) andhexamethylphosphoramide (0.173 ml, 1 mmol) in tetrahydrofuran (2 ml)under nitrogen at 0° C. was add n-butyllithium (0.34 ml, 2.36M inhexane, 0.8 mmol). The resulting mixture was stirred at -78° C. for 10minutes and then a solution of the compound (3a) (0.32 g, 0.53 mmol) intetrahydrofuran (3 ml) was added dropwise. The reaction mixture wasstirred at -78° C. for 30 minutes, then at 0° C. for 30 minutes followedby the addition of methyl iodide (62 μl1.0 mmol) via a syringe. Theresulting mixture is stirred at 0° C. for 10 minutes and warmed toambient temperature over 2 hours. The reaction mixture was then pouredinto cold water and extracted with diethyl ether. The extracts werewashed with water (2×), dried over magnesium sulfate and concentrated invacuo to give an oily residue. The residue was chromatographed oversilica gel eluted with CH₂ Cl₂ :acetone=200:1 (v:v) to a afford thedesired product as a colorless oil: NMR (CDCl₃) δ=0.06 (6H, s), 0.90(9H, s), 1.07 (3H, d, J=7 Hz), 1.35 (3H, s), 4.25 (1H, m), 4.8-5.2 (2H,m), 5.32 (1H, m), 5.50 (1H, m), 5.76 (1H, d of d, J=10 Hz, 5 Hz), 6.00(1H, d, J=10 Hz).

(c)6(R)-[2-[8(S)-(1-Methylcyclobutanecarbonyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-(tert-butyldimethylsilyloxy)-2-hydroxy-3,4,5,6-tetrahydro-2H-pyran(3c)

A mixture of the compound (3b) (0.259 g, 0.42 mmol), toluenesulfonicacid pyridinium salt (70 mg), tetrahydrofuran (6 ml), acetic acid (2 ml)and water (2 ml) was stirred at ambient temperature for 60 hours. Thereaction mixture was poured into cold water and extracted with diethylether. The combined extracts washed with water and 5 percent aqueoussodium bicarbonate, and dried over magnesium sulfate then concentratedin vacuo. The residue was purified by preparative thin layerchromatography over silica gel eluted with methylene chloride:acetone(100:1) to give the desired product: NMR (CDCl₃) δ=0.05 and 0.13 (3H,2s), 0.90 and 0.94 (9H, 2s), 1.07 (3H, d, J=7 Hz), 1.36 (3H, s), 5.80(1H, d of d, J=10 Hz, 5 Hz), 6.00 (1H, d, J=10 Hz).

(d) 6(R)-[2-[8(S)-(1-Methylcyclobutanecarbonyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-(tert-butyldimethylsilyloxy)-3,4,5,6-tetrahydro-2H-pyran-2-one(3d)

To a stirred solution of pyridine (0.218 g, 2.76 mmol) in methylenechloride (6.5 ml) at ambient temperature under nitrogen was added solidchromium oxide (0.138 g, 1.38 mmol). The mixture was stirred for 30minutes and then a solution of the compound (3c) (0.11 g, 0.21 mmol) inmethylene chloride (2.5 ml was added quickly. The reaction mixture wasstirred at ambient temperature for 30 minutes and then filtered throughsilica gel. The silica gel was washed with methylene chloride. Thecombined filtrate and washings were diluted with diethyl ether andwashed successively with dilute hydrochloric acid, and 5 percent aqueoussodium bicarbonate, dried over magnesium sulfate and concentrated invacuo. The residue was purified by preparative thin layer chromatographyover silica gel eluted with methylene chloride:acetone (100:1) to givethe desired product: NMR (CDCl₃) δ=0.08 6H, s), 0.87 (9H, s), 1.08 (3H,d, J=7 Hz), 1.37 (3H, s), 2.60 (2H, d, J=4.5 Hz , 4.27 (1H, m), 4.60(1H, m), 5.31 (1H, m), 5.50 (1H, m), 5.74 (1H, d of d, J=10 Hz, 5 Hz),6.00 (1H, d, J=10 Hz).

(e)6(R)-[2-[8(S)-(1-Methylcyclobutanecarbonyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one

To a stirred solution of the compound (3d) (46 mg, 0.087 mmol) andacetic acid (46 μl0.8 mmol) in tetrahydrofuran (2 ml) was addn-tetrabutylammonium fluoride (0.5 ml, 1M in tetrahydrofuran, 0.5 mmol).The reaction mixture was stirred for 20 hours at ambient temperature.The reaction mixture was then poured into cold water and extracted withdiethyl ether. The combined extracts were washed with 5 percent sodiumbicarbonate, dried over magnesium sulfate and concentrated in vacuo. Theresidue was purified by preparative thin layer chromatography to affordthe desired product, after trituration with diethyl ether/hexane, as asolid, mp 157-9° C.

Anal. Calcd for C₂₅ H₃₆ O₅ ; C, 71.60; H, 9.03.

Found: C, 71.21; H, 8.92.

NMR (CDCl₃) δ=0.91 (3H, d, J=7 Hz), 1.10 (3H, d, J=7 Hz), 1.39 (3H, s),2.63 (1H, s, m of d, J=17 Hz), 2.78 (1H, d of d, J=17 Hz, 5 Hz), 4.40(1H, m), 4.65 (1H, m), 5.40 (1H, m), 5.55 (1H, m), 5.80 (1H, d of d,J=17 Hz, 5 Hz), 6.02 (1H, d, J=10 Hz).

EXAMPLE 4 Preparation of6(R)-[2-[8(S)-(1-Methylthiocyclobutanecarbonyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one(a)6(R)-[2-[8(S)-(1-Methylthiocyclobutanecarbonyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-(tertbutyldimethylsilyloxy)-2-(2-tetrahydropyranyloxy)-3,4,5,6-tetrahydro-2H-pyran(4a)

Utilizinq the general procedure of Example 3(b)but employing methyldisulfide (90 μl, 1 mmol) in place of methyliodide, the compound (3a)(0.23g, 0.38 mmol) was converted into desired product as a yellow oil:NMR (CDCl₃) δ=0.07 (6H, s), 0.88 (9H, s), 1.12 (3H, d, J=7 Hz), 2.02(3H, s), 4.24 (1H, m), 4.85-5.25 (2H, m), 5.37 (1H, m), 5.50 (1H, m),5.75 (1H, d of d, J=10 Hz, 5 Hz), 5.96 (1H, d, J=10 Hz).

(b)6(R)-[2-[8(S)-(1-Methylthiocyclobutanecarbonyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-(tertbutyldimethylsilyloxy)-2-hydroxy-3,4,5,6-tetrahydro-2H-pyran(4b)

Utilizing the general procedure of Example 3(c) the compound (4a) wasconverted into the desired product as a pale yellow oil: NMR (CDCl₃)δ=0.05 and 0.11 (3H, 2s), 0.86 and 0.91 (9H, 2s), 1.10 (3H, d, J=7 Hz),2.02 (3H, s), 5.74 (1H, d of d, J=10 Hz, 5 Hz), 5.96 (1H, d, J=10 Hz).

(c)6(R)-[2-[8(S)-(1-Methylthiocyclobutanecarbonyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-(tertbutyldimethylsilyloxy)-3,4,5,6-tetrahydro-2H-pyran-2-one(4c)

To a stirred mixture of the compound (4b) (0.163 g, 0289 mmol) intoluene (8 ml) was added freshly prepared silver carbonate/celite (0.7g). The reaction mixture was heated under nitrogen on a steam bath for25 minutes. The solid was filtered off and the filtrate concentrated invacuo. The residue was dissolved in toluene (8 ml) treated with silvercarbonate/celite and heated on a steam bath for 25 minutes. This cyclewas repeated for a total of seven times. The final residue was purifiedby preparative thin layer chromatography on silica gel eluted withmethylene chloride:acetone (100:1) to give the desired product as acolorless oil: NMR (CDCl₃) δ=0.08 (3H, s), 0.91 (9H, s), 1.11 (3H, d,J=7 Hz), 2.03 (3H, s), 2.55 (2H, d, J=4 Hz), 4.27 (1H, m), 4.57 (1H, m),5.35 (1H, m), 5.48 (1H, m), 5.74 (1H, d of d, J=10 Hz, 5 Hz), 5.97 (1H,d, J=10 Hz).

(d)6(R)-[2-[8(S)-(1-Methylthiocyclobutanecarbonyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one

Utilizing the general procedure of Example 3(e), the compound (4c) (90mg, 0.16 mmol) was converted into the desired product as an off-whitesolid. mp 134-6° C.

Anal. Calcd for C₂₅ H₃₆ O₅ S: C, 66.93; H, 8.09.

Found: C, 66.79; H, 8.30.

NMR (CDCl₃) δ=0.88 (3H, d, J=7 Hz), 1.12 (3H, d, J=7 Hz), 2.05 (3H, s),4.36 (1H, m), 4.62 (1H, m), 5.3-5.6 (2H, m), 5.75 (1H, d of d, J=10 Hz,5 Hz), 5.97 (1H, d, J=10 Hz).

EXAMPLE 5 Preparation of6(R)-[2-[8(S)-[1-(3-Hydroxypropyl)cyclobutanecarbonyloxy]-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one(a) 1-(tert-Butyldiphenylsilyloxy)propyl iodide (5a)

To a stirred mixture of 3-iodo-1-propanol (4.3 g, 23 mmol) and imidazole(3.74 g, 55 mmol) in dimethylformamide (20 ml) was addedtert-butylchlorodiphenylsilane (6.8 g, 24.7 mmol) at ambient temperatureand the reaction mixture was stirred for 20 hours. The reaction mixturewas then poured into cold water. The combined extracts were washed withdilute hydrochloric acid, 5 percent sodium bicarbonate dried overmagnesium sulfate, and concentrated in vacuo. The residue was purifiedby flash chromatography over silica gel eluted with CH₂ Cl₂ :hexane(1:5, v:v) and further by distillation to afford the desired product asa colorless oil: b.p. 134-5° C./0.01 mmHg.

(b)6(R)-[2-[8(S)-[1-(3-tert-Butyldiphenylsilyloxy)propylcyclobutanecarbonyloxy]-2(S),6(R)dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-(tert-butyldimethylsilyloxy)2-(2-tetrahydropyrenyl)-3,4,5,6-tetrahydro-2H-pyran(5b)

Utilizing the general procedure of Example 3(b) but employing thecompound (5a) (0.596 g, 1.4 mmol) in place of methyliodide, the compound(3a) (0.555 g 0.92 mmol) was converted into the desired product as acolorless viscous oil: NMR (CDCl₃) δ=0.86 (9H, s , 1.04 9H, s), 4.20(1H, m), 4.8-5.2 (2H, m), 5.25-5.55 (2H, m), 5.72 (1H, d of d, J=10 Hz,5 Hz), 5.95 (1H, d, J=10 Hz), 7.25˜7.5 (6H, m), 7.5-7.75 (4H, m).

(c)6(R)-[2-[8(S)-[1-(3-tert-Butyldiphenylsilyloxy)propylcyclobutanecarbonyloxy]-2(S),6(R)dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-(tert-butyldimethylsilyloxy)-2-hydroxy-3,4,5,6-tetrahydro-2H-pyran(5c)

Utilizing the general procedure of Example 3(c), the compound (5b)(0.553 g, 0.61 mmol) was converted into the desired product as a viscousoil: NMR (CDCl₃) δ=0.87 and 0.92 (9H, 2s), 1.05 (9H, s), 3.62 (2H, t,J=6 Hz), 5.75 (1H, d of d, J=10 Hz, 5 Hz), 6.00 (1H, d, J=10 Hz),7.3˜7.5 (6H, m), 7.6-7.8 (4H, m).

(d)6(R)-[2-[8(S)-[1-(3-tert-Butyldiphenylsilyloxy)propylcyclobutanecarbonyloxy]-2(S),6(R)dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-(tert-butyldimethylsilyloxy)-3,4,5,6-tetrahydro-2H-pyran-2-One(5d)

Utilizinq the general procedure of Example 3(d), the compound (5c)(0.192 g, 0.235 mmol) was converted into the desired product as aviscous oil: NMR (CDCl₃) δ=0.05 (6H, s), 0.88 (9H, s), 1.04 (9H, s),2.53 (2H, d, J=4 Hz), 3.60 (2H, t, J=6 Hz), 4.23 (1H, m), 4.57 (1H, m),5.3˜5.6 (2H, m), 5.72 (1H, dd, J=10 Hz, 5 Hz), 5.96 (1H, d, J=10 Hz),7.3˜7.5 (6H, m), 7.5˜7.7 (4H, m).

(e)6(R)-[2-[8(S)-[1-(3-Hydroxypropyl)cyclobutanecarbonyloxy]-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one

Utilizing the general procedure of Example 3(e), the compound (5d)(0.103 g, 0.126 mmol) was converted into the desired product as a glassyoil.

Anal. Calcd for C₂₅ H₄₀ O₆.0.25H₂ O: C, 69.72; H, 8.78.

Found: C, 69.59, H, 8.91. NMR (CDCl₃) δ=0.90 (3H, d, J=7 Hz), 1.13 (3H,d, J=7 Hz), 2.62 (1H, m of d, J=18 Hz), 2.74 (1H, d of d, J=18 Hz, 4Hz), 3.5˜3.7 (2H, m), 4.30 (1H, m), 4.64 (1H, m), 5.40 (1H, m), 5.58(1H, m), 5.79 (1H, d of d, J=10 Hz, 5 Hz) 6.01 (1H, d, J=10 Hz).

EXAMPLE 6 Preparation of6(R)-[2-[8(S)-(1-Hydroxymethyl)cyclobutanecarbonyloxy]-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one(a) Ethyl 1-benzyloxymethylcyclobutanecarboxylate (6a)

n-Butyl lithium solution (2.20 M in hexane, 23.2 ml, 51 mmol) was addedvia a syringe under nitrogen to a stirred solution of di-i-propylamine(5.13 g, 51 mmol) and HMPA (3.5 ml, 20 mmol) in THF (100 ml) at 0° C.The resulting mixture was stirred at 0° C. for 10 minutes, cooled to-78° C., added a solution of ethyl cyclobutanecarboxylate (5 g, 39 mmol)in THF (10 ml) via a dropping funnel. The resulting mixture was stirredat -78° C. for 0.5 hour, then warmed to 0° C. and stirred for 0.5 hour.The mixture was recooled to -78° C., treated with a solution of benzylchloromethyl ether (6.58 g, 42 mmol) in THF (10 ml). The resultingmixture was stirred at -78° C. for 20 minutes, slowly warmed to roomtemperature and stirred for 1 hour. It was poured into cold water,extracted with diethyl ether. The ethereal extract was washedsuccessively with diluted HCl, 5% NaHCO₃, dried, filtered and evaporatedto give a residue. This residue was purified by distillation to affordthe desired product as a pale yellow oil: bp 102-3° C. (0.02 mm); NMR(CDCl₃) δ=1.23 (3H, t, J=7 Hz), 1.6˜2.6 (6H, m), 3.68 (2H, s), 4.15 (2H,q, J=7 Hz), 4.53 (2H, s), 7.30 (5H, s).

(b) Ethyl 1-hydroxymethylcyclobutanecarboxylate (6b)

A mixture of ethyl 1-benzyloxymethylcyclobutanecarboxylate (6.57 g, 26.5mmol), 10% palladium on carbon (0.4 g) and ethanol (100 ml) washydrogenated on a Parr Shaker for 4 hours. The catalyst was removed byfiltration. The filtrate was evaporated in vacuo to leave the desiredproduct as a colorless oil: NMR (CDCl₃) δ=1.26 (3H, t, J=7 Hz), 1.8˜2.6(6H, m), 2.61 (H, s), 3.78 (2H, s), 4.15 (2H, q, J=7 Hz).

(c) 1-Acetoxymethylcyclobutanecarboxylic Acid (6c)

Sodium hydroxide pellets (1.48 g, 37 mmol) was added to a stirredmixture of ethyl 1-hydroxymethylcyclobutanecarboxylate (4.14 g, 26.1mmol), water (4 ml) and 95% ethanol (20 ml). The resulting mixture wasstirred at room temperature overnight, then concentrated on a rotaryevaporator. The residue was treated with toluene (100 ml). Evaporationof this mixture gave a flaky residue which was further dried under highvacuum. The final residue was treated with pyridine (25 ml) and aceticanhydride (15 ml). The resulting mixture was stirred at room temperaturefor 18 hours, then heated on a steam bath for 20 minutes. It was cooledto room temperature, added crushed ice, then slowly treated withconcentrated HCl (12N, 30 ml) with vigorous stirring. It was extractedwith a mixture of diethyl ether (120 ml) and methylene chloride (40 ml).The extract was washed with water (4×100 ml), dried, filtered andevaporated to yield the desired product as a yellow oil: NMR (CDCl₃)δ=1.82-2.7 (9H, m containing a singlet at 2.076δ), 4.40 (2H, s), 11.46(H, bs).

(d) 1-Acetoxymethylcyclobutanecarbonyl chloride (6d)

Thionyl chloride (1.65 ml, 22.7 mmol) was added to neat1-acetoxymethylcyclobutanecarboxylic acid (3.3 g, 18.9 mmol). Theresulting mixture was stirred at room temperature for 1 hour, thenheated on a steam bath for 5 minutes. After cooling, the excess thionylchloride, HCl and SO₂ were removed under reduced pressure (wateraspirator). The remained residue was purified by distillation to providethe desired product as a colorless oil: bp 51-3° C. (0.02 mm); NMR(CDCl₃) δ=1.8˜2.7 (9H, m containing a singlet at 2.04 δ), 4.40 (2H, s).

(e)6(R)-[2-[8(S)-(1-Acetoxymethyl)cyclobutanecarbonyloxy]-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-(tertbutyldimethylsilyloxy)-3,4,5,6-tetrahydro-2H-pyran-2-one(6e)

By following the general procedure described in Example 1(a) but usingcompound 6(d) in place of 1-methylcyclopropanecarbonyl chloride, therewas obtained the desired 6(e) as a pale yellow oil: NMR (CDCl₃) δ=0.08(6H, s), 0.89 (9H, s), 1.05 (3H, d, J=7 Hz), 1.98 (3H,s), 2.57 (2H, d,J=4 Hz), 4.30 (2H, s), 4.31 (H, m), 4.62 (H, m), 5.47 (2H, m), 5.73 (H,d of d, J=10.5 Hz), 6.00 (H, d, J=10 Hz).

(f)6(R)[2-[8(S)-(1-Acetoxymethyl)cyclobutanecarbonyloxy]-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6,-tetrahydro-2H-pyran-2-one(6f)

Utilizing the general procedure of Example 1(b), the compound 6(e) wasconverted to the desired product as a yellow oil: NMR (CDCl₃) δ=0.90(3H, d, J=7 Hz), 1.06 (3H, d, J=7 Hz), 2.00 (3H, s), 2.72 (2H, d, J=4Hz), 3.35 (H, bs), 4.30 (2H, s), 4.40 (H, m), 4.70 (H, m), 5.3˜5.6 (2H,m), 5.78 (H, d of d, J=10, 5 Hz), 6.00 (H, d, J=10 Hz).

(g)6(R)-[2-[8(S)-(1-Hydroxymethyl)cyclobutanecarbonyloxy]-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one

Sodium hydroxide (1N, 2.5 ml, 25 mmol) was added to a stirred mixture ofcompound 6(f) (0.432 g, 0.91 mmol) in methanol (10 ml) and acetonitrile(1 ml). The resulting mixture was stirred at 0° C. for 10 minutes, thenwarmed to room temperature and stirred for 2 hours. The reaction mixturewas diluted with water, acidified with HCl (2N, 2.5 ml) and extractedwith methylene chloride twice. The combined extracts were dried,filtered and evaporated to leave a residue which was dissolved inbenzene (15 ml), heated at reflux for 1.5 hours. After the evaporation,the solid residue was purified by flash chromatography on a silica gelcolumn. Elution of the column with methylenechloride:acetone:i-propanol=20:2:1 (v:v:v) gave the desired product as awhite solid which was recrystallized from methylene chloride-hexane: mp162-5° C.; NMR (CDCl₃) δ=0.91 (3H, d, J=7 Hz), 1.12 (3H, d, J=7 Hz),3.75˜3.95 (2H, m), 4.39 (H, m), 4.65 (H, m), 5.48 (H, m), 5.58 (H, m),5.81 (H, d of d, J=10, 5 Hz), 6.04 (H, d, J=10 Hz). Anal Calcd for C₂₅H₃₆ O₆ : C, 69.42; H, 8.39.

Found: C, 69.51; H, 8.44.

EXAMPLE 7 Preparation of6(R)-[2-[8(S)-(1-Methylcyclopentanecarbonyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one

By following the general procedures described in Example 3(a) to (e),and using cyclopentanecarbonyl chloride to replace cyclobutanecarbonylchloride, the above titled compound was prepared.

(a)6(R)-[2-[8(S)-(Cyclopentanecarbonyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-(tert-butyldimethylsilyloxy)-2-(2-tetrahydropyranyloxy)-3,4,5,6-tetrahydro-2H-pyran(7a)

NMR (CDCl₃) δ=0.05 (6H, s), 0.90 (9H, d), 1.09 (3H, d, J=9 Hz), 4.25(1H, m) 4.8˜b 5.2 (2H, m), 5.31 (1H, m), 5.53 (1H, m), 5.77 (1H, d of d,J=10, 5 Hz, 6.00 (1H, d, J=10 Hz).

(b)6(R)-[2-[8(S)-(1-Methylcyclopentanecarbonyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-(tert-butyldimethylsilyloxy)-2-(2-tetrahydyropyranyloxy)-3,4,5,6-tetrahydro-2H-pyran(7b)

NMR (CDCl₃) δ=0.06 (6H, s), 0.90 (9H, s), 1.10 (3H, d, J=7 Hz), 1.24(3H, s) 4.25 (1H, m), 4.8˜5.2 (2H, m), 5.30 (1H, m), 5.50 (1H, m), 5.75(1H, d of d, J=10, 5 Hz), 5.99 (1H, d, J=10 Hz).

(c)6(R)-[2-[8(S)-(1-Methylcyclopentanecarbonyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-(tert-butyldimethylsilyloxy)-2-hydroxy-3,4,5,6-tetrahydro-2H-pyran(7e)

NMR (CDCl₃) δ=0.90 and 0.94 (9H, two s), 1.08 (3H, d, J=7 Hz), 1.20 (3H,s), 5.74 (1H, d of d, J=10, 5 Hz), 5.97 (1H, d, J=10 Hz). (d)6(R)-[2-[8(S)-(1-Methylcyclopentanecarbonyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-(tert-butyldimethylsilyloxy)-3,4,5,6,-tetrahydro-2H-pyran

2-one (7d) NMR (CDCl₃) δ=0.07 (6H, s), 0.88 (9H, s), 1.07 (3H, d, J=7Hz), 1.20 (3H, s), 2.55 (2H, d, J=4 Hz), 4.27 (1H, m), 4.57 (1H, m),5.30 (1H, m), 5.50 (1H, m), 5.75 (1H, d of d, J=10, 5 Hz), 6.00 (1H, d,J=10 Hz).

(e)6(R)-[2-[8(S)-(1-Methylcyclopentanecarbonyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one

m.p. 148˜51° C.; NMR (CDCl₃) δ=0.89 (3H, d, J=7 Hz), 1.07 (3H, d, J=7Hz) 1.21 (3H, s), 4.35 (1H, m), 4.68 (1H, m), 5.35 (1H, m), 5.50 (1H,m), 5.75 (1H, d of d, J=10, 5 Hz), 6.00 (1H, d, J=10 Hz).

EXAMPLE 8 Preparation of6(R)-[2-[8(S)-(1-Methylthiocyclopentanecarbonyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one

By following the general procedures described in Example 4 and usingcompound 7(a) instead of compound 3 (b), the above-title compound wasprepared.

(a)6(R)-[2-[8(S)-(1-Methylthiocyclopentanecarbonyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a-(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-(tertbutyldimethylsilyloxy)-2-(2-tetrahydropyranyloxy)-3,4,5,6,-tetrahydro-2H-pyran(8a)

NMR (CDCl₃) δ=0.05 6H, s), 0.90 (9H, s), 1.13 (3H, d, J=7 Hz), 2.08 (3H,s), 4.27 (1H, m), 4.9˜5.3 (2H, m), 5.3˜5.7 (2H, m), 5.85 (1H, d of d,J=10, 5 Hz), 6.05 (1H, d, J=10 Hz).

(b)6(R)-[2-[8(S)-(1-Methylthiocyclopentanecarbonyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a-(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-(tert-butyldimethylsilyloxy)-2-hydroxy-3,4,5,6-tetrahydro-2H-pyran(8b)

NMR (CDCl₃) δ=0.04 and 0.13 (6H, two s), 0.90 and 0.94 (9H, two s), 1.14(3H, d, J=7 Hz), 2.10 (3H, s), 5.79 (1H, d of d, J=10, 5 Hz), 6.03 (1H,d, J=10 Hz).

(c)6(R)-[2-[8(S)-(1-Methylthiocyclopentanecarbonyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-(tertbutyldimethylsilyloxy)-3,4,5,6-tetrahydro-2H-pyran-2-one(8c)

NMR (CDCl₃) δ=0.11 (6H, s), 0.89 (9H, s), 1.10 (3H, d, J=7 Hz), 2.07(3H, s) 2.55 (2H, d, J=4 Hz), 4.24 (1H, m), 4.53 (1H, m), 5.24 (1H, m),5.45 (1H, m), 5.72 (1H, d of d, J=10, 5 Hz), 5.95 (1H, d, J=10 Hz).

(d)6(R)-[2-[8(S)-(1-Methylthiocyclopentanecarbonyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a-(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy3,4,5,6-tetrahydro-2H-pyran-2-one

NMR (CDCl₃) δ=0.90 (3H, d, J=7 Hz), 1.11 (3H, d J=7 Hz), 2.10 (3H, s),2.62 (1H, m of d, J=17 Hz), 2.76 (1H, d of d, J=17, 5 Hz) 4.38 (1H, m),4.62 (1H, m), 5.38 (1H, m), 5.53 (1H, m), 5.78 (1H, d of d, J=10, 5 Hz),5.98 (1H, d, J=10 Hz): ms (M+1)⁺ =463.

EXAMPLE 9 Preparation of6(R)-[2-[8(S)-[(1-Phenylmethyl)cyclobutanecarbonyloxy]-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one(a) Ethyl 1-Phenylmethylcyclobutanecarboxylate (9a)

Utilizing the general procedure described in Example 6(a) but usingbenzyl chloride in place of benzyl chloromethyl ether, there wasobtained the desired product as a pale yellow oil: bp 88-91° C. 0.5 mm);NMR (CDCl₃) δ=1.15 (3H, t, J=7 Hz), 1.6˜2.6 (6H, m), 3.10 2H, s), 4.10(2H, q, J=7 Hz), 7.20 (5H, bs).

(b) 1-Phenvlmethylcyclobutanecarboxylic Acid (9b)

A mixture of ethyl 1-phenylmethylcyclobutanecarboxylate (4.16 g, 19.1mmol), sodium hydroxide (1.2 g, 30 mmol) in ethanol (95%, 20 ml andwater (5 ml) was stirred at room temperature for 60 hours. The reactionmixture was poured into cold water and extracted with diethyl ether. Theaqueous Phase was separated, acidified with HCl (2N, 35 ml) andextracted with diethyl ether. The latter extract was washed with water,dried, filtered and evaporated to afford the desired product as a paleyellow oil: NMR (CDCl₃) δ=1.7˜2.6 (6H, m), 3.10 (2H, s), 7.22 (5H, s).

(c) 1-Phenylmethylcyclobutanecarbonyl Chloride (9c)

Utilizing the general procedure described in Example 6(d), compound 9(b)was converted to the desired product as a colorless oil: bp 78-81° C.(0.01 mm); NMR (CDCl₃) δ=1.7˜2.7 (6H, m), 3.20 (2H, s), 7.23 (5H, m).

(d)6(R)-[2-[8(S)-[(1-Phenylmethyl)cyclobutanecarbonyloxy]-2(S),6(R)-dimethyl-1,2,6,7,8,8a-(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-(tertbutyldimethylsilyloxy)-3,4,5,6-tetrahydro-2H-pyran-2-One(9d)

Utilizing the general procedure described in Example 1(a) but usingcompound 9(c) in place of 1-methylcyclopropanecarbonyl chloride, therewas obtained the desired product as a yellow oil: NMR (CDCl₃) δ=0.07(6H, s), 0.89 (9H, s), 2.55 (2H, d, J=4 Hz), 2.95 (H, d, J=15 Hz), 3.15(H, d, J=15 Hz), 4.27 (H, m), 4.53 (H, m), 5.45 (2H, m), 5.72 (H, d ofd, J=10, 5 Hz), 5.98 (H, d, J=10 Hz), 7.17 (5H, bs).

(e)6(R)-[2-[8(S)-[(1-Phenylmethyl)cyclobutanecarbonyloxy]-2(S),6(R)-dimethyl-1,2,6,7,8,8a-(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one

Utilizing the general procedure described in Example 1(b), compound 9(d)was converted to the desired product as a glassy gum: NMR (CDCl₃) δ=0.86(3H, d, J=7 Hz), 0.87 (3H, d, J=7 Hz), 2.61 (H, m of d, J=16 Hz), 2.74(H, d of d, J=16, 7 Hz), 3.04 (H, d, J15 Hz), 3.15 (H, d, J=15 Hz), 4.34(H, m), 4.54 (H, m), 5.48 (2H, m), 5.77 (H, d of d, J=10, 5 Hz), 5.99(H, d, J=10 Hz), 7.14˜7.28 (5H, m).

Anal. Calcd for C₃₁ H₄₀ O₅.0.5H₂ O: C, 74.22; H, 8.24.

Found: C, 74.12; H, 8.14.

EXAMPLE 10 Preparation of6(R)-[2-[8(S)-[1-[(4-hydroxyphenyl)methyl]cyclobutanecarbonyloxy]-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4-(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one

By following the same procedures described in Example 6, steps (a)-(g),but using 4-benzyloxybenzyl chloride in place of benzyl chloromethylether in the first step, there were obtained successively:

(a) Ethyl 1-(4-Benzyloxyphenyl)methylcyclobutanecarboxylate (10a)

NMR (CDCl₃) δ1.20 (3H, t, J=7 Hz), 1.7˜2.5 (6H, m), 3.0 (2H, s), 4.08(2H, q, J=7 Hz), 5.0 (2H, s), 6.82 (2H, d, J=8 Hz), 7.03 (2H, d, J=8Hz), 7.36 (5H, m).

(b) Ethyl 1-(4-Hydroxyphenyl)methylcyclobutanecarboxylate (10b)

NMR (CDCl₃) δ=1.20 (3H, t, J=7 Hz), 1.6˜2.6 (6H, m), 3.0 (2H, s), 4.12(2H, q, J=7 Hz), 6.68 (2H, d, J=8 Hz), 6.95 (2H, d, J=8 Hz).

(c) 1-(4-Acetoxyphenyl)methylcyclobutanecarboxylic Acid (10c)

NMR (CDCl₃) δ=1.7˜2.7 (6H, m), 2.31 (3H, s), 3.10 (2H, s), 6.95 (2H, d,J=8 Hz), 7.13 (2H, d, J=8 Hz), 10.96 (H, bs).

(d) 1-(4-Acetoxyphenyl)methylcyclobutanecarbonyl chloride

NMR (CDCl₃) δ=1.7˜2.7 (6H, m), 2.24 (3H, s), 3.18 (2H, s), 7.05 (2H, d,J=8 Hz), 7.22 (2H, d, J=8 Hz).

(e)6(R)-[2-[8(S)-[1-(4-Acetoxyphenyl)methylcyclobutanecarbonyloxy]-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-(tert-butyldimethylsilyloxy)-3,4,5,6-tetrahydro-2H-pyran-2-one(10e)

NMR (CDCl₃) δ=0.1 (6H, s), 0.89 (9H, s), 2.36 (3H, s), 2.57 (2H, d, J=4Hz), 2.95 (H, d, J=14 Hz), 3.17 (H, d, J=14 Hz), 4.30 (H, m), 4.60 (H,m), 5.50 (2H, m), 5.74 (H, d of d, J=10, 5 Hz), 6.00 (H, d, J=10 Hz),6.95 (2H, d, J=8 Hz), 7.17 (2H, d, J=8 Hz).

(f)6(R)-[2-[8(S)-[1-(4-Acetoxyphenyl)methylcyclobutanecarbonyloxy]-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one(10f)

NMR (CDCl₃) δ=0.87 (3H, d, J=7 Hz), 0.91 (3H, d, J=7 Hz), 2.26 (3H,s),2.98 (H, d, J=14 Hz), 3.18 (H, d, J=14 Hz), 4.28 (H, m), 4.50 (H, m),5.46 (2H, m), 5.77 (H, d of d, J=10, 5 Hz), 6.01 (H, d, J=10 Hz), 6.99(2H, d, J=8 Hz), 7.17 (2H, d, J=8 Hz).

(g)6(R)-[2-[8(S)-[1-[(4-Hydroxyphenyl)methyl]cyclobutanecarbonyloxy]-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one(10g)

NMR (CDCl₃) δ=0.82 (3H, d, J=7 Hz), 1.04 (3H, d, J=7 Hz), 2.63 (H, m ofd, J=17 Hz), 2.78 (H, d of d, J=17, 5 Hz), 3.03 (H, d, J=15 Hz), 3.16(H, d, J=15 Hz), 4.40 (2H, m), 5.31 (H, m), 5.49 (H, m), 5.75 (H, d ofd, J=10, 5 Hz), 5.98 (H, d, J=10 Hz), 6.72 (2H, d, J=8 Hz), 7.03 (2H, d,J=8 Hz).

Anal. Calcd for C₃₁ H₄₀ O₆ : C, 73.20; H, 7.93.

Found C, 72.94; H, 8.27.

EXAMPLE 11-16

Utilizing the general procedures from Example 1 to 4 the followingcompounds are prepared from the appropriate starting materials:

    ______________________________________                                        Com-                                                                          pound                                                                         ______________________________________                                        11                                                                                   ##STR31##                                                              12                                                                                   ##STR32##                                                              13                                                                                   ##STR33##                                                              14                                                                                   ##STR34##                                                              15                                                                                   ##STR35##                                                              ______________________________________                                    

EXAMPLE 16 Preparation of Alkali and Alkaline Earth Salts of Compound II

To a solution of 42 mg of the lactone from Example 1 in 2 ml of ethanolis added 1 ml of aqueous NaOH (1 equivalent). After one hour at roomtemperature, the mixture is taken to dryness in vacuo to yield thesodium salt of Compound II.

In like manner the potassium salt is prepared using one equivalent ofpotassium hydroxide, and the calcium salt using one equivalent of CaO.

EXAMPLE 17 Preparation of Methyl Ester of Compound II

To a solution of 400 mg of the lactone from Example 1 in 100 ml ofabsolute methanol is added 10 ml 0.1 M sodium methoxide in absolutemethanol. This solution is allowed to stand at room temperature for onehour, is then diluted with water and extracted twice with ethyl acetate;the ethyl acetate, dried over anhydrous sodium sulfate, is removed invacuo to yield the methyl ester of Compound II.

In like manner, by the use of equivalent amounts of propanol, butanol,isobutanol, t-butanol, amyl alcohol, isoamyl alcohol,2-dimethylaminoethanol, benzyl alcohol, phenethanol, 2-acetamidoethanol,and the like, the corresponding esters are obtained.

EXAMPLE 18 Preparation of free Hydroxy Acids

The sodium salt of the compound II from Example 16 is redissolved in 2ml of ethanol-water (1:1) and added to 10 ml of 1N hydrochloric acidfrom which the hydroxy acid is extracted with ethyl acetate. The lattersolvent is washed once with water, dried, and removed in vacuo with abath temperature not exceeding 30° C. The hydroxy acid derived slowlyreverts to the lactone on standing.

EXAMPLE 19

As a specific embodiment of a composition of this invention, 20 mg ofthe lactone from Example 1 is formulated with sufficient finely dividedlactose to provide a total amount of 580 to 590 mg to fill a size 0 hardgelatin capsule.

What is claimed is:
 1. A compound represented by the following generalstructural formula (II): ##STR36## wherein: n is 2 to 7;R¹ is C₁₋₆ alkylsubstituted with a group selected from halogen or hydroxy; C₁₋₆alkylthio; phenylmethyl or 4-hydroxyphenylmethyl; A is ##STR37## b and drepresent single bonds, or both b and d represent double bonds; Z ishydrogen, C₁₋₅ alkyl or C₁₋₅ alkyl substituted with a group selectedfrom phenyl, dimethylamino or acetylamino; andpharmaceuticallyacceptable salts of the compounds of the formula (II) in which Z ishydrogen.
 2. A compound of claim 1 whereinn is 2 to 5; and R¹ is C₁₋₆alkyl; hydroxy-C₁₋₆ alkyl; C₁₋₆ alkylthio; phenylmethyl; or4-hydroxyphenylmethyl.
 3. A compound of claim 2 wherein n is
 2. 4. Acompound of claim 2 wherein n is
 3. 5. A compound of claim 2 wherein nis
 4. 6. A compound of claim 2 wherein n is
 5. 7. A hypocholesterolemic,hypolipidemic pharmaceutical composition comprising a nontoxictherapeutically effective amount of a compound of claim 1 and apharmaceutically acceptable carrier.
 8. A composition according to claim7 wherein:n is 2 to 5;and R¹ is C₁₋₆ alkyl; hydroxy-C₁₋₆ alkyl; C₁₋₆alkylthio; phenyl; or hydroxyphenyl.
 9. A hypocholesterolemic,hypolipidemic pharmaceutical composition comprising a nontoxictherapeutically effective amount of a compound of claim 1 in combinationwith a pharmaceutically acceptable nontoxic cationic polymer capable ofbinding bile acids in a non-reabsorbable form in the gastrointestinaltract and a pharmaceutically acceptable carrier.
 10. A method ofinhibiting cholesterol biosynthesis comprising the administration to asubject in need of such treatment a nontoxic therapeutically effectiveamount of a compound of claim
 1. 11. A method of claim 10 wherein:n is 2to 5; and R¹ is C₁₋₆ alkyl hydroxy-C₁₋₆ alkyl; C₁₋₆ alkylthio; phenyl;or hydroxyphenyl.
 12. A compound of claim 3 which is 7-[1,2,6,7,8, 8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-(1-methylcyclopropanecarbonyloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid.
 13. A compound of claim 4, which is7-[1,2,6,7,8, 8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-(1-methylcyclobutanecarbonyloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid.
 14. A compound of claim 4 which is7-[1,2,6,7,8, 8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-(1-methylthiocyclobutanecarbonyloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoicacid.
 15. A compound of claim 4 which is 7-[1,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-[1-(3-hydroxypropyl)cyclobutanecarbonyloxy]-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoicacid.
 16. A compound of claim 4 which is7-[1,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-[1-[(4-hydroxyphenyl)methyl]cyclobutanecarbonyloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoicacid.
 17. A compound of claim 4 which is 7-[1,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-[1-(hydroxymethyl)cyclobutanecarbonyloxy]-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoicacid.
 18. A compound of claim 4 which is 7-[1,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-8 1-(1-phenylmethyl)cyclobutanecarbonyloxy]-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoicacid.
 19. A compound of claim 5 which is 7-[1,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-(1-methylcyclopentanecarbonyloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoicacid.
 20. A compound of claim 5 which is 7-[1,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-(1-methylthiocycopentanecarbonyl)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoicacid.
 21. A compound of claim 6 which is 7-[1,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-(1-methylcyclohexanecarbonyloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoicacid.
 22. A composition according to claim 8 wherein the therapeuticallyactive ingredient is selected from the group consisting of(1)7-[1,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-(1-methylcyclopropanecarbonyloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoicacid; (2)7-[1,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-(1-methylcyclobutanecarbonyloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoicacid; (3)7-[1,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-(1-methylthiocyclobutanecarbonyloxy)-1(S)naphthyl]-3(R),5(R)-dihydroxyheptanoicacid; (4)7-[1,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-(1-(3-hydroxypropyl)cyclobutanecarbonyloxy]1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoicacid; (5)7-[1,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-[1-[(4-hydroxyphenyl)methyl]-cyclobutanecarbonyloxy]-3(R),5(R)-dihydroxyheptanoicacid; (6)7-[1,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-[(1-hydroxymethyl)cyclobutanecarbonyloxy]-3(R),5(R)-dihydroxyheptanoicacid; (7)7-[1,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-[1-(1-phenylmethyl)cyclobutanecarbonyloxy]-3(R),5(R)-dihydroxyheptanoicacid; (8) 7-[1,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-(1-methylcyclopentanecarbonyloxy]-3(R),5(R)-dihydroxyheptanoic acid;(9)7-[1,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-(1-methylthiocyclopentanecarbonyl)-3(R),5(R)-dihydroxyheptanoic acid; (10)7-[1,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-(1-methylcyclocyclohexanecarbonyloxy)-3(R),5(R)-dihydroxyheptanoic acid.
 23. A method of claim 11 wherein thetherapeutically active ingredient is selected from the group consistingof:(1)6(R)-[2-[8(S)-[(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-(1-methylcyclopropanecarbonyloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoicacid; (2)7-[1,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-(1-methylcyclobutanecarbonyloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoicacid; (3)7-[1,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-(1-methylthiocyclobutanecarbonyloxy)-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoicacid; (4)7-[1,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-(1-(3-hydroxypropyl)cyclobutanecarbonyloxy]-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoicacid; (5)7-[1,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-[1-[(4-hydroxyphenyl)methyl]cyclobutanecarbonyloxy]-3(R),5(R)-dihydroxyheptanoicacid; (6)7-[1,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-[(1-hydroxymethyl)cyclobutanecarbonyloxy]-3(R),5(R)-dihydroxyheptanoicacid; (7)7-[1,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-[1-(1-phenylmethyl)cyclobutanecarbonyloxy]-3(R),5(R)-dihydroxyheptanoicacid; (8)7-[1,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-(1-methylcyclopentanecarbonyloxy]-3(R),5(R)-dihydroxyheptanoic acid; (9)7-[1,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-(1-methylthiocyclopentanecarbonyl)-3(R),5(R)-dihydroxyheptanoic acid; (10)7-[1,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-(1-methylcyclocyclohexanecarbonyloxy)-3(R),5(R)-dihydroxyheptanoic acid.